EGFR and cancer: The MAPK signaling pathway has been reported to be activated in cancer drug resistant samples, and its abnormal activation could contribute to cell loss of differentiation and apoptosis [27], and could be a mechanism of resistance to osimertinib in EGFR-mutated NSCLC [28].